The Watt laboratory has identified an additional mechanism of ceramide accrual in muscle in type 2 diabetic patients, involving LDL-mediated transport of ceramides and uptake by myotubes, which is sufficient to induce systemic insulin resistance by mediating decreased insulin action in muscle [265]. The gene discussed is INS; the disease is type 2 diabetes mellitus.